This article highlights the latest guidance on appropriate dosing of direct-acting oral anticoagulants (DOACs) in people with non-valvular atrial fibrillation (NVAF). Key considerations include specific dose adjustment requirements for each DOAC and the importance of improving patient adherence with DOAC therapy.
Document Number: PP-XAR-GB-2774
Date of Preparation: April 2022
Date of Preparation: April 2022
